デイリーニュース

The Korean Pharmaceutical Association’s Patient Safety Drug Management Center hosted a symposium titled “Redefining the Role of Pharmacies in Patient Safety,” reviewing drug monitoring achievements and future directions.

The Korean Hospital Pharmacists Association announced the final selection of nine teams, with Busan University Hospital winning the Grand Prize in its first‑ever patient safety and quality improvement contest.

Novartis paused its autologous CD19 CAR‑T program (rapcabtagene autoleucel) after three patients died from severe immune adverse events. Bristol Myers Squibb also stopped enrollment in a similar trial.

Korean Hospital Pharmacists Association and Society of Hospital Medicine call for formal multidisciplinary teams—including hospitalists, ward pharmacists, and support nurses—to improve patient safety and reduce medication errors.

WHO designates September 17 as World Patient Safety Day, urging global participation to improve patient safety and develop related policies.

Professor Moon Jeong‑yeon highlighted the need for pharmacist‑driven medication reconciliation to cut medication errors during hospital admissions, discharges and transfers.

Ritpulo capsule, a JAK inhibitor for severe alopecia areata, must be preceded by TB and viral hepatitis testing and requires ongoing infection monitoring.

The JAK‑inhibitor for severe alopecia areata, Ritpulocapsule (ritlecitinib), mandates pre‑treatment TB and viral hepatitis checks and continuous infection monitoring during therapy.

The Songpa-gu Pharmacists Association held its second half‑year training for 2026, distributing a newly created Zolpidem standard counseling checklist to members.